Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 16/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23519846 | 0.84 | KMT2A (0.48) | GRIN2BHTR2AHTR2CKRAS | |
| SCHEMBL18911998 | 0.83 | HTR2A (0.40) | HTR2AHTR2CKRAS | |
| SCHEMBL21936808 | 0.82 | KRAS (0.41) | HTR2AHTR2CKRAS | |
| SCHEMBL21936469 | 0.82 | GRIN2B (0.55) | GRIN2BGRIN1KCNH2HTR2AHTR2C | |
| SCHEMBL24901027 | 0.76 | HTR2A (0.46) | HTR2AHTR2C | |
| SCHEMBL18912161 | 0.75 | HTR2A (0.40) | HTR2AHTR2CKRAS | |
| SCHEMBL3354522 | 0.70 | GRIN2B (0.45) | GRIN2BGRIN1 | |
| SCHEMBL18912153 | 0.70 | CYP2A6 (0.41) | HTR2AHTR2C | |
| SCHEMBL13981018 | 0.69 | HTR2C (0.54) | GRIN2BGRIN1HTR2AHTR2C | |
| SCHEMBL8568248 | 0.69 | KMT2A (0.65) | GRIN2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| WO-2017090756-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | INMT, CARM1, KDM1B | GRIN2B 2642/4885GRIN1 1485/4885KCNH2 3038/4885 |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, KDM1A, HDAC1 | GRIN2B 1569/4885GRIN1 1828/4885KCNH2 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.